Objective: Our aim was to evaluate the effect of low dose pregabalin on weight, balance, gait, fatigue, and sleepiness in fibromyalgia patients in a twelve-week follow-up period in this study. Material and Methods: Twenty-eight patients with fibromyalgia diagnosis were included in the study. All patients used 150 mg/day pregabalin during the study period and they were followed for twelve weeks. Weight, body mass index measurements, Tinetti Balance and Gait Test, Epworth Sleepiness Scale, and Fatigue Severity Scale were performed prior to the treatment, at the fourth week, and at the twelfth week of the study. The results at these time points were compared. Results: Among 28 patients who accepted to participate in the study, 11 patients dropped out of the study. Seven of these patients dropped out due to adverse effects. The weight significantly increased at the 4th (p=0.010) and 12th weeks of treatment (p=0.008) compared to the pretreatment measurements. The mean weight gain was 1.5±1.8 kg at the 4th week and 1.7±1.9 kg at the 12th week compared to the baseline. There were no statistically significant differences in the parameters of the Tinetti Balance Test, Tinetti Gait Test, Epworth Sleepiness Scale, and Fatigue Severity Scale scores before and after the treatment periods. Conclusion: Low dose pregabalin induces weight gain in patients with fibromyalgia. Pregabalin does not have a significant effect on gait, balance, sleepiness, and fatigue